Quantoom Biosciences

Greater access and autonomy through innovation in bioproduction

We are on a mission to remove the barriers to making mRNA-based vaccines & therapeutics,
at every stage from sequence up to mass production.

Who We Are

Quantoom Biosciences, a Univercells company, is reinventing mRNA production by developing an RNA Platform that encompasses DNA and RNA manufacturing and formulation, along with critical reagent supply, from sequence to large scale production.

We are a team of scientists, engineers and clinicians committed to solving some of the biggest DNA and RNA production challenges facing vaccines and therapeutics, by delivering greater access and autonomy to mRNA technology.

In December 2021, we expanded our team with the acquisition of SynHelix which specializes in synthetic DNA and enzyme engineering.

Our facilities are strategically located in Belgium and France, in the heart of Europe, benefiting from an exceptional biotech ecosystem.

Who We Are

Quantoom Biosciences, a Univercells company, is reinventing mRNA production by developing an RNA Platform that encompasses DNA and RNA manufacturing and formulation, along with critical reagent supply, from sequence to large scale production.

We are a team of scientists, engineers and clinicians committed to solving some of the biggest DNA and RNA production challenges facing vaccines and therapeutics, by delivering greater access and autonomy to mRNA technology.

In December 2021, we expanded our team with the acquisition of SynHelix which specializes in synthetic DNA and enzyme engineering.

Our facilities are strategically located in Belgium and France, in the heart of Europe, benefiting from an exceptional biotech ecosystem.

what we do

At Quantoom Biosciences, we are bringing radical innovation to the way mRNA is produced in any research lab, biotech biopharma and CDMO. We support our partners early on with sequence design & candidate screening up to (pre-)clinical development toward a successful mRNA product.

Our technologies are based on our Intensification and chaining engineering principles that deliver small footprint, automated and cost-effective bioproduction technologies.

More specifically, we have developed:

what we do

At Quantoom Biosciences, we are bringing radical innovation to the way mRNA is produced in any research lab, biotech biopharma and CDMO. We support our partners early on with sequence design & candidate screening up to (pre-)clinical development toward a successful mRNA product.

Our technologies are based on our Intensification and chaining engineering principles that deliver small footprint, automated and cost-effective bioproduction technologies.

More specifically, we have developed:

Our GMP-grade RNA Production System

We designed our RNA Production System with end users’ needs in mind, creating a radically different manufacturing technology with two features at its core.

These features deliver a set of benefits for mRNA drug developers;

Key numbers:

Up to 20 g per day (5 kg per year) of purified mRNA per system

Up to 100 million doses (50 µg) per year

Our GMP-grade RNA Production System

We designed our RNA Production System with end users’ needs in mind, creating a radically different manufacturing technology with two features at its core.

These features deliver a set of benefits for mRNA drug developers;

Key numbers:
  • Up to 20 g per day (5 kg per year) of purified mRNA per system
  • Up to 100 million doses (50 µg) per year

What makes us different

We deliver access and autonomy through innovation
innovation - Disruptive innovation as the driver of everything we do
Access - Lower entry barriers to drug development and production
Autonomy - Self-sufficient production up to commercial scale

What makes us different

We deliver access and autonomy through innovation
innovation - Disruptive innovation as the driver of everything we do
Access - Lower entry barriers to drug development and production
Autonomy - Self-sufficient production up to commercial scale

Enabling more organisations to explore a wider range of
product development opportunities to get to treatments faster.

Enabling more organisations to explore a wider range of product development opportunities to get to treatments faster.

Our Team

Our team consists of international experts whose talent, experience and commitment
make the company a key player in therapeutic development and biomanufacturing.

Management Team

José Castillo

Chief Executive Officer
(and Univercells Co-Founder)

Kristof Vandekerckhove

Chief Scientific Officer & Head of Research BE

Yves Ghislain

Head of Technical Development & Operations

Conor Cahill

Head of Product Development

Irina Gbalou

Head of Research FR

Guillaume Roelandts

Head of Commercial Operations

Rachana Talwar

Head of PMO & Chief of Staff

Strategic & Scientific Advisory Board